Therapeutic management of allergic diseases.
Allergic diseases are characterized by the activation of inflammatory cells and by a massive release of mediators. The aim of this chapter was to describe succinctly the modes of action, indications, and side effects of the major antiallergic and antiasthmatic drugs. When considering the ideal pharmacokinetic characteristics of a drug, a poorly metabolized drug may confer a lower variability in plasma concentrations and metabolism-based drug interactions, although poorly metabolized drugs may be prone to transporter-based disposition and interactions. The ideal pharmacological properties of a drug include high binding affinity, high selectivity, and appropriate association and dissociation rates. Finally, from a patient perspective, the frequency and route of administration are important considerations for ease of use.
Watelet
Jean-Baptiste
JB
Department of Otohinolaryngology, Head and Neck Surgery, Ghent University Hospital, Ghent University, Belgium. jeanbaptiste.watelet@ugent.be
Gillard
Michel
M
Benedetti
Margherita Strolin
MS
Lelièvre
Bénédicte
B
Diquet
Bertrand
B
D000818:Animals; D018926:Anti-Allergic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism; D015195:Drug Design; D004347:Drug Interactions; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D008407:Mast Cells / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D015394:Molecular Structure; D017060:Patient Satisfaction
D018926:Anti-Allergic Agents; D018927:Anti-Asthmatic Agents